Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022–2024 Period
Stephanie H. Read, Lucie Kutikova, Gaelle Gusto, Raissa Kapnang, Nadia Quignot, Artak Khachatryan, Clotilde El Guerche-Séblain, Vincent Petit, Jonathan Fix, Matthew D. Rousculp, Cécile Janssen, Odile Launay · 2026
Read Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022–2024 Period by Stephanie H. Read, Lucie Kutikova, Gaelle Gusto, Raissa Kapnang, Nadia Quignot, Artak Khachatryan, Clotilde El Guerche-Séblain, Vincent Petit, Jonathan Fix, Matthew D. Rousculp, Cécile Janssen, Odile Launay (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13611775.txt.
Description
Stephanie Read and co-authors track use of the Novavax COVID-19 vaccine in France in a 2026 study. The protein based vaccine was approved in France in late 2021 as an alternative to other COVID shots. National health data cover five vaccine seasons from spring 2022 to spring 2024. The team profiles who got the shot each season.
Recipient counts fell sharply after the first season, then steadied at low levels. The mix of recipients changed a lot. By spring 2024, most were at high risk or aged sixty-five and over, far above early shares. Heart disease also grew much more common among recipients.
Catalog record
| CREATOR | Stephanie H. Read, Lucie Kutikova, Gaelle Gusto, Raissa Kapnang, Nadia Quignot, Artak Khachatryan, Clotilde El Guerche-Séblain, Vincent Petit, Jonathan Fix, Matthew D. Rousculp, Cécile Janssen, Odile Launay |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |